Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice.
Muralidharan C, Huang F, Enriquez JR, Wang JE, Nelson JB, Nargis T, May SC, Chakraborty A, Figatner KT, Navitskaya S, Anderson CM, Calvo V, Surguladze D, Mulvihill MJ, Yi X, Sarkar S, Oakes SA, Webb-Robertson BM, Sims EK, Staschke KA, Eizirik DL, Nakayasu ES, Stokes ME, Tersey SA, Mirmira RG. Muralidharan C, et al. Among authors: calvo v. J Clin Invest. 2024 Jun 18;134(16):e176136. doi: 10.1172/JCI176136. J Clin Invest. 2024. PMID: 38889047 Free PMC article.
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.
Stokes ME, Calvo V, Fujisawa S, Dudgeon C, Huang S, Ballal N, Shen L, Gasparek J, Betzenhauser M, Taylor SJ, Staschke KA, Rigby AC, Mulvihill MJ, Bose N, Lightcap ES, Surguladze D. Stokes ME, et al. Among authors: calvo v. Clin Cancer Res. 2023 Dec 1;29(23):4870-4882. doi: 10.1158/1078-0432.CCR-23-1182. Clin Cancer Res. 2023. PMID: 37733811 Free PMC article.
Inhibition of the Eukaryotic Initiation Factor-2-α Kinase PERK Decreases Risk of Autoimmune Diabetes in Mice.
Muralidharan C, Huang F, Enriquez JR, Wang JE, Nelson JB, Nargis T, May SC, Chakraborty A, Figatner KT, Navitskaya S, Anderson CM, Calvo V, Surguladze D, Mulvihill MJ, Yi X, Sarkar S, Oakes SA, Webb-Robertson BM, Sims EK, Staschke KA, Eizirik DL, Nakayasu ES, Stokes ME, Tersey SA, Mirmira RG. Muralidharan C, et al. Among authors: calvo v. bioRxiv [Preprint]. 2024 Jun 3:2023.10.06.561126. doi: 10.1101/2023.10.06.561126. bioRxiv. 2024. Update in: J Clin Invest. 2024 Jun 18;134(16):e176136. doi: 10.1172/JCI176136. PMID: 38895427 Free PMC article. Updated. Preprint.
A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
Calvo V, Zheng W, Adam-Artigues A, Staschke KA, Huang X, Cheung JF, Nobre AR, Fujisawa S, Liu D, Fumagalli M, Surguladze D, Stokes ME, Nowacek A, Mulvihill M, Farias EF, Aguirre-Ghiso JA. Calvo V, et al. Clin Cancer Res. 2023 Dec 15;29(24):5155-5172. doi: 10.1158/1078-0432.CCR-23-1427. Clin Cancer Res. 2023. PMID: 37982738 Free PMC article.
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors.
Calvo V, Surguladze D, Li AH, Surman MD, Malibhatla S, Bandaru M, Jonnalagadda SK, Adarasandi R, Velmala M, Singireddi DRP, Velpuri M, Nareddy BR, Sastry V, Mandati C, Guguloth R, Siddiqui S, Patil BS, Chad E, Wolfley J, Gasparek J, Feldman K, Betzenhauser M, Wiens B, Koszelak-Rosenblum M, Zhu G, Du H, Rigby AC, Mulvihill MJ. Calvo V, et al. Bioorg Med Chem Lett. 2021 Jul 1;43:128058. doi: 10.1016/j.bmcl.2021.128058. Epub 2021 Apr 23. Bioorg Med Chem Lett. 2021. PMID: 33895276 Free article.
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
Molina-Alejandre M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, Casarrubios M, Casal-Rubio J, Martinez-Martí A, Insa A, Massuti B, Viteri S, Barneto Aranda I, Rodriguez-Abreu D, de Castro J, Martínez JM, Cobo M, Wistuba II, Parra ER, Martín-López J, Megías D, Muñoz-Viana R, Garrido F, Aptsiauri N, Ruiz-Cabello F, Provencio M, Cruz-Bermúdez A. Molina-Alejandre M, et al. Among authors: calvo v. J Immunother Cancer. 2024 Oct 20;12(10):e009762. doi: 10.1136/jitc-2024-009762. J Immunother Cancer. 2024. PMID: 39428126 Free PMC article.
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García Campelo R, Casal J, Dómine M, Massuti B, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro J, Gómez de Antonio D, Macia I, Figueroa S, Fernández Vago L, Calvo V, Palmero R, Sierra-Rodero B, Martínez-Toledo C, Molina-Alejandre M, Serna-Blasco R, Romero A, Cruz-Bermúdez A. Provencio M, et al. Among authors: calvo v. Lancet Oncol. 2024 Nov;25(11):1453-1464. doi: 10.1016/S1470-2045(24)00498-4. Epub 2024 Oct 14. Lancet Oncol. 2024. PMID: 39419061 Free PMC article. Clinical Trial.
Quality of care assessment for non-small cell lung cancer patients: transforming routine care data into a continuous improvement system.
Sánchez JC, Nuñez-García B, Garitaonaindia Y, Calvo V, Blanco M, Ramos Martín-Vegue A, Royuela A, Manso M, Cantos B, Méndez M, Collazo-Lorduy A, Provencio M. Sánchez JC, et al. Among authors: calvo v. Clin Transl Oncol. 2024 Aug 16. doi: 10.1007/s12094-024-03658-3. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39147937
253 results